Moreover, our results revealed that the ac4C modification and NAT10 expression levels are increased in GC and that NAT10 expression is associated with poor prognosis in patients with GC; furthermore, the inclusion of NAT10 expression can increase the predictive ability of clinical risk scores, suggesting that NAT10 may be a diagnostic biomarker for GC. Here, NAT10 is linked to gastric cancer.